Arrowhead Pharmaceuticals Faces Pivotal Week with Key FDA Decision and Earnings Report

Investor attention is firmly fixed on Arrowhead Pharmaceuticals this week as the biotechnology firm approaches two significant milestones that could dramatically influence its trajectory. With the stock having surged more than 85% since the start of the year, the market is questioning whether this momentum can be sustained or if the company is poised for a setback.

Before the market opens on November 25, Arrowhead is scheduled to release its full-year financial results. Market experts are projecting earnings of $0.13 per share for the most recent quarter. A critical point of analysis will be the company’s cash position. Management has previously indicated that its existing liquid assets are sufficient to fund Read more...